Actively Recruiting

Phase 4
Age: 19Years +
All Genders
NCT06218199

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Led by Heart Center Research, LLC · Updated on 2024-01-29

80

Participants Needed

1

Research Sites

286 weeks

Total Duration

On this page

Sponsors

H

Heart Center Research, LLC

Lead Sponsor

B

Boston Scientific Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.

CONDITIONS

Official Title

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Boston Scientific device with HeartLogic enabled
  • No standard contraindications to sacubitril/valsartan such as history of ACE-inhibitor or ARB induced angioedema, hypotension, hypovolemia, renal artery stenosis, renal failure, hyperkalemia, severe hepatic disease, or pregnancy/breast-feeding
  • No standard contraindications to diuretic therapy
  • Systolic blood pressure greater than 105 mmHg
Not Eligible

You will not qualify if you...

  • Glomerular filtration rate below 25 mL/min with non-responsiveness to diuretics or on chronic renal dialysis
  • Current symptoms of heart failure worsening such as increased shortness of breath or fatigue
  • Recent significant change in arrhythmia burden within 2 weeks
  • Recent change in cardiac resynchronization therapy delivery within 60 days
  • Unable or unwilling to sign informed consent
  • Symptomatic heart failure at rest or New York Heart Association Class IV at enrollment
  • Implanted with unipolar right atrial or right ventricular leads
  • Received or planned heart transplant or ventricular assist device within 6 months
  • Pregnant or planning pregnancy during the study
  • Regularly scheduled intravenous heart failure treatments such as inotropes or diuretics

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Heart Center Research, LLC

Huntsville, Alabama, United States, 35801

Actively Recruiting

Loading map...

Research Team

C

COO

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here